Propensity-Weighted Survival Analysis of SBRT vs. Conventional Radiotherapy in Unfavorable Intermediate-Risk Prostate Cancer-Reference-Cited by-同舟云学术

Propensity-Weighted Survival Analysis of SBRT vs. Conventional Radiotherapy in Unfavorable Intermediate-Risk Prostate Cancer

Published:2021-12 Issue: Volume: Page:
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Andruska Neal^ORCID,Fischer-Valuck Benjamin W.,Agabalogun Temitope,Carmona Ruben,Brenneman Randall J.^ORCID,Huang Yi^ORCID,Gay Hiram A.,Michalski Jeff M.,Baumann Brian C.

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference29 articles.

1. Prostate alpha/beta revisited – an analysis of clinical results from 14 168 patients;Dasu;Acta Oncol,2012

2. A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low;King;Int J Radiat Oncol Biol Phys,2001

3. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9-2.2) Gy;Miralbell;Int J Radiat Oncol Biol Phys,2012

4. Hypofractionated radiation therapy for localized prostate cancer: an ASTRO, ASCO, and AUA evidence-based guideline;Morgan;J Clin Oncol,2018

5. Confirmation of a low alpha/beta ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics;Proust-Lima;Int J Radiat Oncol Biol Phys,2011

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Variation in Androgen Deprivation Therapy Use Among Men With Intermediate-Risk Prostate Cancer: Results From a Statewide Radiation Oncology Quality Consortium;International Journal of Radiation Oncology*Biology*Physics;2024-06

2. Acute Large Dose Irradiation Sensitizes Surviving Cells to Subsequent Irradiation; Implications for Stereotactic Body Radiation Therapy;Radiation Research;2024-03-08

3. CT-based online adaptive radiotherapy improves target coverage and organ at risk (OAR) avoidance in stereotactic body radiation therapy (SBRT) for prostate cancer;Clinical and Translational Radiation Oncology;2024-01